Additionally, lenvatinib directly induced cancer cell death due to its inhibitory effects on tyrosine kinases such as FGFR, which is associated with the release of damage-associated molecular patterns, including HMGB1, from dying cancer cells, known as immunogenic cell death (ICD) [53]. This evidence concerns the gene HMGB1 and cancer.